Communiqués Olema Pharmaceuticals, Inc.

Actions

OLMA

US68062P1066

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 01/10/2026			Varia. 5j.	Varia. 1 janv.
8,270 ^USD	-4,28%		-6,34%	-66,92%

15/09	Transcript : Olema Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 01:50 PM
14/09	Les plus fortes baisses en avant-Bourse	MT

Communiqués

02/09	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
31/08	Olema Oncology to Participate in Upcoming Investor Conferences	GL
14/08	Olema Oncology Appoints Jason O'Byrne as Chief Financial Officer	AQ
13/08	Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer	GL
10/08	Olema Oncology Reports Second Quarter 2026 Financial and Operating Results	GL
05/08	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 4, 2026	AQ
04/08	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
02/07	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
02/06	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
26/05	Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer	GL
21/05	Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting	GL
19/05	Olema Oncology to Participate in Upcoming Investor Conferences	GL
12/05	Olema Oncology Reports First Quarter 2026 Financial and Operating Results	GL
04/05	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
29/04	Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors	GL
21/04	Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting	GL
17/04	Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting	GL
02/04	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
17/03	Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting	GL
16/03	Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results	GL
03/03	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
19/02	Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference	GL
04/02	Olema Oncology to Participate in Upcoming Investor Conferences	GL
03/02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
30/01	Olema Oncology Announces Departure of Chief Operating and Financial Officer	GL